期刊文献+

雷珠单抗玻璃体内注射、全视网膜光凝和黄斑光凝联合治疗糖尿病黄斑水肿的临床疗效 被引量:21

Clinical Effect of Treatment with a Combination of Lucentis Intravitreal Injection and Whole Retinal and Macular Photo Coagulation in Patients with Diabetic Macular Edema
暂未订购
导出
摘要 目的评价单纯玻璃体内注射雷珠单抗注射液、单纯采用全视网膜光凝联合黄斑格栅样光凝和玻璃体内注射雷珠单抗注射液联合全视网膜光凝同时黄斑格栅样光凝治疗糖尿病黄斑水肿(DME)的临床疗效。方法通过光学相干断层扫描(OCT)和眼底荧光血管造影(FFA)筛选符合条件的DME患者(共60眼),随机分为3组:单纯注药组(开始时、4周、8周时注药),单纯激光组(全视网膜光凝同时黄斑格栅样光凝治疗)和玻璃体内注射雷珠单抗注射液联合全视网膜光凝同时黄斑格栅样光凝联合治疗组(联合治疗组,于注药1周行全视网膜光凝同时黄斑格栅样光凝治疗),每组各20眼。比较3组治疗后1周、4周、8周、12周的最佳矫正视力(BCVA)及黄斑中心凹视网膜厚度(CMT)变化。结果联合治疗组注药后1、4、8、12周BCVA和CMT与术前及组间比较均有统计学差异(均P <0.05)。单纯注药组在相应时间点BCVA和CMT与术前比较有统计学差异(P <0.05),与单纯激光组8周内比较有统计学差异(P <0.05),12周2组间比较无统计学差异(P> 0.05)。单纯激光组术后4周BCVA和CMT与术前比较无统计学差异(P> 0.05),12周时与术前比较有统计学差异(P <0.05)。联合治疗组与单纯注药组治疗后与术前比较BCVA均明显提高;联合治疗组治疗后12周与8周时比较BCVA显著升高。单纯激光组术后4周内视力提高不明显,个别患者加重黄斑水肿、视力下降,但8周后与单纯注药组比较无明显差异。结论玻璃体内注射雷珠单抗注射液联合全视网膜光凝同时黄斑格栅样光凝治疗DME能够有效提高患者视力,降低CMT。 Objective To evaluate the clinical effect,including best corrected visual acuity(BCVA),of lucentis intravitreal injection,photocoagulation,and combined lucentis intravitreal injection and photocoagulation,in patients with diabetic macular edema.Methods In total 42 patients(60 eyes)with edema were randomly divided into three groups:the combined group(treated with lucentis intravitreal injection and laser therapy),injection group(treated with lucentis intravitreal injection alone),and laser group(laser treatment alone).We compared the treatment effects among the three groups,including the impact on the central retinal thickness(CMT),and BCVA.Results After treatment for 1,4,8,and 12 weeks,the CMT and BCVA in the combined group and the injection group were significantly different from those before treatment(P<0.05,each).After treatment for 8,and 12 weeks,the CMT and BCVA in the laser group were significantly different from those before treatment(P<0.05,each).The BCVA in the combined group and the injection group were significantly higher than that before treatment.After treatment for 1 and 4 weeks,the BCVA in the laser group did not increase from that before treatment;moreover,the individual patients showed aggravated macular edema,resulting in decreased vision.After treatment for 8 weeks,the BCVA in the laser group did not increase significantly in comparison to the injection group.Conclusion The combination of lucentis intravitreal injection and laser treatment in patients with diabetic macular edema showed synergistic effects to significantly reduce macular edema-induced CMT and improve BCVA.
作者 于秀玲 徐丽 刘驰 YU Xiuling;XU Li;LIU Chi(Department of Ophthalmology,The Fourth People’s Hospital of Shenyang,Shenyang 110031,China)
出处 《中国医科大学学报》 CAS CSCD 北大核心 2018年第11期1011-1014,共4页 Journal of China Medical University
基金 沈阳市科学技术计划(F16-206-9-25)
关键词 糖尿病视网膜病变/并发症 黄斑水肿 雷珠单抗 全视网膜光凝 黄斑格栅样光凝 联合治疗 diabetic retinopathy/complication macular edema lucentis panretinal photocoagulation macular grid pattern photocoagulation combined treatment
  • 相关文献

参考文献3

二级参考文献29

  • 1齐慧君,黎晓新.糖尿病性黄斑水肿的激光治疗[J].眼科,2005,14(4):234-236. 被引量:35
  • 2张玮,山本香织,堀贞夫.糖尿病黄斑水肿玻璃体手术治疗1a预后(英文)[J].国际眼科杂志,2005,5(6):1097-1103. 被引量:10
  • 3Gupta N,Mansoor S,Sharma A,et al.Diabetic retinopathy and VEGF.Open Ophthalmol J 2013; 7:4-10.
  • 4Shahin MM, El-Lakkany RS. A prospective, randomized comparison of intravitreal triamcinolone acetonide versus intravitreal Bevacizumab(Avastin)in diffuse diabetic macular edema.Middle East Afr J Ophthalmol 2010; 17(3):250-253.
  • 5Ehrlich R, Harris A, Ciulla TA, et al. Diabetic macular edema:physical, physiological and molecular factors contribute to this pathological. Acta Ophthalmologica 2010; 88(3):279-291.
  • 6Early Treatment Diabetic Retinopathy Study Reserch Group.Treatment techniques and clinical guidelines for photocogagulation of diabetic macular edema.Early teratment of diabetic retinopathy study report number 1.Arch Ophthalmol 1985; 103(12):1796-1806.
  • 7Yamamoto T, Hitani K, Sato Y, et al.Vitrectomy for diabetic macular edema with and without intemal limiting membrane removal.Ophthalmologica 2005; 219(4):206-213.
  • 8Hufendiek K, Hufendiek K, Panagakis G, et al.Visual and morphological outcomes of bevacizumab(Avastin&#xAE; versus ranibizumab(Lueentis&#xAE;)treatment for retinal angiomatous proliferation.Int Ophthalmol 2012; 32(3):259-268.
  • 9Nguyen QD,Shah SM,Khwaja AA,et al. Two-year outcome of the ranibizumab for edema of the macula in diabites(READ.2)study. Ophthalmology 2010; 117(11):2146-2151.
  • 10Massin P, Bandello F, Garweg JG, et al.Safety and efficacy of ranibizumab in diabetic macular edema(RESOLVE Study):a 12-month,randomized,controlled,double masked,muhicenter phase II study.Diabetes Care 2010; 33(11):2399-2405.

共引文献12

同被引文献165

引证文献21

二级引证文献74

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部